CAC 40
7 526,55 +98,03 (+1,32 %) Euro Stoxx 50
4 523,31 +49,54 (+1,11 %) Dow Jones
36 247,87 +130,49 (+0,36 %) EUR/USD
1,0764 -0,0034 (-0,31 %) Gold future
2 020,80 -25,60 (-1,25 %) Bitcoin EUR
40 730,41 +692,77 (+1,73 %)
MRK Jun 2024 105.000 call
| Clôture précédente | 6,25 |
| Ouverture | 5,80 |
| Offre | 6,00 |
| Vente | 6,25 |
| Prix d’exercice | 105,00 |
| Date d’expiration | 2024-06-21 |
| Var. jour | 5,80 - 5,80 |
| Gamme de contrats | S.O. |
| Volume | |
| Position de place | 2,68k |
ACCESSWIREMRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA) for the adjuvant
- ACCESSWIRE
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful
